Erectile Dysfunction

Managing erectile dysfunction in heart failure - Abstract

Published on Thursday, 23 May 2013 07:44

Nowadays, erectile dysfunction (ED) is considered an increasingly important clinical condition in men with heart failure (HF) which might influence the therapeutic approach to these patients.

Male circumcision is not associated with an increased prevalence of erectile dysfunction : Results of the Cottbus 10,000-men survey - Abstract

Published on Wednesday, 22 May 2013 07:09

BACKGROUND: There are conflicting data regarding the significance of the presence of the male prepuce or circumcision on erectile function and sexual satisfaction in men.

Initial and subsequent success with PDE5 inhibitor treatment for erectile dysfunction: Results of a pooled analysis of a large integrated clinical trial database, "Beyond the Abstract," by Angelina Sontag, PhD and Raymond Rosen, PhD

Published on Wednesday, 22 May 2013 00:00

BERKELEY, CA (UroToday.com) - Erectile dysfunction (ED) affects a majority of men by the time they reach their 60s.^[1]

Arterial erectile dysfunction: Different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil - Abstract

Published on Tuesday, 21 May 2013 15:58

BACKGROUND: The low pharmacological response to phosphodiesterase type 5 inhibitors represents an expression of higher endothelial damage in certain categories of patients with erectile dysfunction and high cardiovascular risk.

"Beyond the Abstract," Metabolic syndrome, hormone levels, and inflammation in patients with erectile dysfunction, by Miguel Angel Arrabal-Polo, PhD

Published on Friday, 17 May 2013 15:26

BERKELEY, CA (UroToday.com) - In our recent article, we studied the differences between a group of patients with erectile dysfunction, compared to a control group.

A systematic review assessing the economic impact of sildenafil citrate (Viagra(®) ) in the treatment of erectile dysfunction - Abstract

Published on Thursday, 16 May 2013 14:59

INTRODUCTION: Sildenafil was the first oral phosphodiesterase type 5 (PDE5) inhibitor introduced as primary therapy for erectile dysfunction (ED).

Adjunctive treatment with lodenafil carbonate for erectile dysfunction in outpatients with schizophrenia and spectrum: A randomized, double-blind, crossover, placebo-controlled trial - Abstract

Published on Wednesday, 15 May 2013 16:38

INTRODUCTION: Evidence is accumulating to support the presence of erectile dysfunction in patients with schizophrenia.

The identification of prediabetes condition with ARIC algorithm predicts long-term CV events in patients with erectile dysfunction - Abstract

Published on Tuesday, 14 May 2013 16:36

INTRODUCTION: The Atherosclerosis Risk in Communities (ARIC) algorithm is one of the most efficient instruments for the prediction of incident type 2 diabetes.

Impaired masturbation-induced erections: A new cardiovascular risk factor for male subjects with sexual dysfunction - Abstract

Published on Monday, 13 May 2013 16:40

INTRODUCTION: Erectile dysfunction (ED) is considered an early surrogate marker of silent, or even overt, cardiovascular diseases (CVD).

Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus - Abstract

Published on Friday, 10 May 2013 16:26

INTRODUCTION: Phosphodiesterase type 5 inhibitors PDE5Is are less effective in diabetic men with erectile dysfunction (ED); however, the effect of combination therapy with folic acid and PDE5Is in these patients has not been investigated.

Page 1 of 42

Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End